Skip to main content

Table 2 Subjects with Adverse Events*

From: Subcutaneously administered Menopur(R), a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex(R) in subjects undergoing in vitro fertilization

Adverse Event

Menopur® (n = 61)

Repronex® (n = 64)

P Value

Any

41

(67.2)

48

(75.0)

0.620

Severe

5

(8.2)

5

(7.8)

0.402

Serious

1

(1.6)

4

(6.3)

0.456

  1. *Values represent numbers (percentage) of subjects with one or more adverse event.
Back to article page

Reproductive Biology and Endocrinology

ISSN: 1477-7827

Contact us